GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Shiller PE Ratio

NeoGenomics (NeoGenomics) Shiller PE Ratio : (As of Jun. 08, 2024)


View and export this data going back to 1996. Start your Free Trial

What is NeoGenomics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


NeoGenomics Shiller PE Ratio Historical Data

The historical data trend for NeoGenomics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Shiller PE Ratio Chart

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NeoGenomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeoGenomics's Shiller PE Ratio

For the Diagnostics & Research subindustry, NeoGenomics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Shiller PE Ratio falls into.



NeoGenomics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

NeoGenomics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, NeoGenomics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.21/131.7762*131.7762
=-0.210

Current CPI (Mar. 2024) = 131.7762.

NeoGenomics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.010 100.560 0.013
201409 -0.010 100.428 -0.013
201412 0.020 99.070 0.027
201503 -0.010 99.621 -0.013
201506 -0.003 100.684 -0.004
201509 -0.002 100.392 -0.003
201512 -0.030 99.792 -0.040
201603 -0.070 100.470 -0.092
201606 -0.070 101.688 -0.091
201609 -0.070 101.861 -0.091
201612 -0.180 101.863 -0.233
201703 -0.050 102.862 -0.064
201706 -0.030 103.349 -0.038
201709 -0.090 104.136 -0.114
201712 0.030 104.011 0.038
201803 -0.030 105.290 -0.038
201806 0.070 106.317 0.087
201809 0.020 106.507 0.025
201812 0.004 105.998 0.005
201903 -0.030 107.251 -0.037
201906 0.020 108.070 0.024
201909 0.020 108.329 0.024
201912 0.060 108.420 0.073
202003 -0.070 108.902 -0.085
202006 -0.060 108.767 -0.073
202009 0.020 109.815 0.024
202012 0.130 109.897 0.156
202103 -0.190 111.754 -0.224
202106 0.590 114.631 0.678
202109 -0.170 115.734 -0.194
202112 -0.340 117.630 -0.381
202203 -0.400 121.301 -0.435
202206 -0.280 125.017 -0.295
202209 -0.300 125.227 -0.316
202212 -0.180 125.222 -0.189
202303 -0.250 127.348 -0.259
202306 -0.190 128.729 -0.194
202309 -0.150 129.860 -0.152
202312 -0.110 129.419 -0.112
202403 -0.210 131.776 -0.210

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NeoGenomics  (NAS:NEO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


NeoGenomics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics (NeoGenomics) Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
Executives
Alicia C Olivo officer: General Counsel 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan officer: Chief Accounting Officer HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman officer: Chief Financial Officer 103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris officer: President, Enterprise Ops 4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez director 12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith officer: Chief Executive Officer 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni officer: President of Lab Operations 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri officer: President and CCO, Inivata 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello officer: VP, Investor Relations 12780 WESTLINKS DRIVE, FORT MYERS FL 33913
Kathryn B Mckenzie officer: Principal Accounting Officer 12780 WESTLINKS DRIVE, FORT MYERS FL 33913